IMRA News and Press, IMARA Inc. From 03/05/21

Imara, Inc. (IMRA) Q4 2020 Earnings Conference Call March 05, 2021, 08:30 ET Company Participants Michael Gray - CFO & COO Rahul Ballal - President, CEO & Director Conference Call Participants Matthew Harrison - Morgan Stanley Kelly Girskis - SVB Leerink Presentation Operator Ladies a...

Gainers: Second Sight Medical Products (EYES) +337%.AMTD International (HKIB) +27%.Sify Technologies Limited (SIFY) +26%.Boqii Holding Limited (BQ) +25%.ChromaDex Corporation (CDXC) +22%.W&T Offshore (WTI) +21%.Anchiano Therapeutics (ANCN) +18%.Purple Innovation (PRPL) +19%.Plus Ther...

Imara shares slide ([[IMRA]] -18.6%) after the company reported full-year results and provided financial forecast for 2021.Net loss was $49.2M, or $3.53/share, for the year ended December 31, 2020, compared to a net loss of $23.5M, or $33.40/share last year.Research and development expenses w...

Imara (IMRA): FY GAAP EPS of -$3.53 misses by $0.27.Cash, cash equivalents and investments of $88.2M.FY21 guidance:  Research and development expenses in the range of $50M-55M; general and administrative expenses in the range of $12M-14M.Press Release For further details see: ...

Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a open label extension clinical trial data Company to host conference call and live webcast today at 8:30...

BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wi...

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that Rahul Ballal, ...

BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The three major U.S. stock averages ended Friday at all-time highs despite a weak December jobs report, in a session that zigzagged with the hopes of furth...

Imara (IMRA) closed in red, down 38% yesterday as investors apparently saw the company's sickle cell data lacked benefit when compared to its peers.Data showed that IMR-687 had no meaningful impact on key measures like fetal hemoglobin ((HbF)) or hemoglobin levels when taken by itse...